View in EDS

Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial.

Saved in:

Bibliographic Details
Title:	Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial.
Authors:	Krop IE; Yale Cancer Center, New Haven, CT., Mittempergher L; Agendia, Amsterdam, the Netherlands., Paulson JN; Genentech, San Francisco, CA., Andre F; Gustave Roussy, Paris, France., Bonnefoi H; Bergonie Cancer Institute, Bordeaux, France., Loi S; Peter MacCallum Cancer Centre, Melbourne, Australia., Loibl S; Goethe University, Frankfurt, Germany., Gelber RD; Dana-Farber Cancer Institute, Harvard Medical School, Harvard TH Chan School of Public Health, and Frontier Science Foundation, Boston, MA., Caballero C; Breast International Group (BIG), Brussels, Belgium., Bhaskaran R; Agendia, Amsterdam, the Netherlands., Dreezen C; Agendia, Amsterdam, the Netherlands., Menicucci AR; Agendia, Amsterdam, the Netherlands., Bernards R; Agendia, Amsterdam, the Netherlands., van 't Veer LJ; Agendia, Amsterdam, the Netherlands., Piccart MJ; Breast International Group (BIG), Brussels, Belgium.
Source:	JCO precision oncology [JCO Precis Oncol] 2024 Jan; Vol. 8, pp. e2200667.
Publication Type:	Journal Article; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	2473-4284
DOI:	10.1200/PO.22.00667